Nearly two years after moving his venture Insilico Medicine from the US to Hong Kong, Alex Zhavoronkov has grown more convinced of the view that the future of the world’s pharmaceutical industry lies in mainland China – especially with what he has observed in recent months – a trend of “much more aggressive” dealmaking efforts in the region.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
